Dr. Michelle Caird is an Assistant Professor of Orthopaedic Surgery at the University of Michigan. She is a busy member of the Division of Pediatric Orthopaedics. She received an engineering degree from The University of Michigan, followed by medical school at The University of Michigan where she earned Alpha Omega Alpha honors. She completed her internship and residency in orthopaedic surgery at The University of Michigan, and fellowship training in Pediatric Orthopaedic Surgery at the Children’s Hospital of Philadelphia.
Dr. Caird joined the faculty at the University of Michigan at the completion of fellowship. Clinically, she treats multiple orthopaedic conditions faced by children including fractures, spinal deformity, unequal or bowed legs, clubfeet, and complex hip problems in growing children. Her areas of special expertise include treating fractures and spinal deformity in children with osteogenesis imperfecta, spina bifida, and cerebral palsy and in the laboratory, she investigates bone healing in these diseases. She is currently a member of the Board of Directors of the Pediatric Orthopaedic Society of North America (POSNA) and she recently was selected to represent POSNA in Northern Europe as one of the 2012 POSNA Traveling Fellows where she studied and taught at major European centers. Dr. Caird is Board Certified by the American Board of Orthopaedic Surgery, and is a member of the American Academy of Orthopaedic Surgeons, the Scoliosis Research Society, and the Pediatric Orthopaedic Society of North America.
Treatment of scoliosis and spinal disorders in children; treatment of pediatric fractures; causes and treatment of osteogenesis imperfecta.
Benjamin P. Sinder; Joseph D. Salemi; Michael S. Ominsky; Michelle S. Caird; Joan C. Marini; Kenneth M. Kozloff. Rapidly growing Brtl/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment. Bone. 2015;71:115-123.
Sinder BP, White LE, Salemi JD, Ominsky MS, Caird MS, Marini JC, Kozloff KM. Adult Brtl/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to Sclerostin antibody treatment with increased bone mass and strength. Osteoporosis International. 2014;25(8):2097-107. PMID: 24803333.
Meganck JA, Begun DL, McElderry JD, Swick A, Kozloff KM, Goldstein SA, Morris MD, Marini JC, Caird MS. Fracture healing with alendronate treatment in the Brtl/+ mouse model of osteogenesis imperfecta. Bone 2013;56(1):204-212. PMID: 23774443